Korro Bio, Inc. (KRRO)

Market Cap	494.15M
Revenue (ttm)	n/a
Net Income (ttm)	-81.17M
Shares Out	8.02M
EPS (ttm)	-53.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,075
Open	58.44
Previous Close	58.53
Day's Range	57.18 - 62.24
52-Week Range	9.15 - 97.91
Beta	n/a
Analysts	Strong Buy
Price Target	126.25 (+102.84%)
Earnings Date	May 27, 2024

About KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 3, 2019
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: KRRO

Analyst Forecast

According to 4 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price forecast is $126.25, which is an increase of 102.84% from the latest price.

Price Target

$126.25

(102.84% upside)

Analyst Consensus: Strong Buy